Skadden, Arps, Slate, Meagher & Flom and Davis Polk & Wardwell have advised on Chinese biotech company 3SBio Inc’s $712 million IPO on the Hong Kong Stock Exchange.
3SBio, which delisted from the Nasdaq two years ago, priced its IPO at the top of expectations, and will use the capital raised to fund acquisitions and recruit staff, reported IFR, a Thomson Reuters publication.
The company and shareholder CITIC Private Equity offered 606.1 million shares, which were priced at HK$9.10 each, the top of a marketing range of HK$8.30 to HK$9.10, according to IFR.
Skadden advised 3SBio on its listing, with a team led by partner Peter Huang in Beijing and partners Christopher Betts and Will Cai in Hong Kong. Jingtian & Gongcheng was the biotech company’s PRC legal counsel, while Bonelli Erede Papalargo and Conyers Dill & Pearman provided advice on Italian and Cayman Islands law, respectively.
Citic Securities, Goldman Sachs and Morgan Stanley were the joint sponsors of the deal, and were represented by Davis Polk & Wardwell and JunHe.
3SBio’s listing was announced on June 1, and shares began trading on June 11.
